

3737

PTO/SB/21 (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	<b>Application Number</b>	09/842,148	
	<b>Filing Date</b>	04/26/2001	
	<b>First Named Inventor</b>	Struble	
	<b>Group Art Unit</b>	3737	
	<b>Examiner Name</b>		
<b>Total Number of Pages in This Submission</b>	16+	<b>Attorney Docket Number</b>	P-9440.00

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input checked="" type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
<b>Remarks</b> Box Patent Application Commissioner for Patents Washington, D.C. 20231 16 Pages plus references		RECEIVED JAN 31 2003 TECHNOLOGY CENTER R3700

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
<b>Firm or Individual name</b>	Medtronic, Inc., USPTO Customer No. 27581 Eric R. Waldkoetter, Reg. No. 36,713
<b>Signature</b>	<i>Eric R. Waldkoetter</i> 31 43 356-6845 TEL 31 43 356-6521 FAX
<b>Date</b>	27 JAN 2003

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: <span style="border: 1px solid black; display: inline-block; width: 100px; height: 15px;"></span>			
<b>Typed or printed name</b>			
<b>Signature</b>		<b>Date</b>	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



*#7/Supple*  
*EDS*

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s):	Struble	)	Examiner:
		)	
App. No.	09/842,148	)	Art Unit: 3737
		)	
Filed:	04/26/2001	)	
		)	
Conf. No.	6240	)	
		)	
Title:	Drug delivery treatment of cardiac	)	
	arrhythmia	)	
		)	
Docket No.	P-9440.00	)	

**RECEIVED**

**JAN 31 2003**

TECHNOLOGY CENTER R3700

Box Patent Application  
Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

The attached information disclosure statement form and references are submitted under 1.97(b)(3) without fee because either the statement is within three months of the filing date of a national applications, before the mailing of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. It is respectfully requested that the examiner consider these documents.


This disclosure statement should not be construed as representation that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists. Some documents may have markings on them, but no significance should be attributed to the markings. It is believed that this disclosure complies with the requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98, and the M.P.E.P. § 609. If for some reason the examiner considers otherwise, it is respectfully requested that the undersigned be called so that any deficiency can be remedied.

Recognizing that Internet communications are not secure, I hereby authorize the USPTO to communicate with me concerning any subject matter of this application by electronic mail at the address below. I understand that a copy of these communications will be made of record in the application file. M.P.E.P. § 502.03.

Respectfully submitted,

Date: 27 JAN 2003  
Medtronic, Inc.  
USPTO Customer No. 27581  
710 Medtronic Parkway (MS-LC340)  
Minneapolis, MN 55432-5604

*Attachment:* Information Disclosure  
Statement Form

  
Eric R. Waldkoetter  
Attorney Reg. No. 36,713  
Located in The Netherlands (ET + 6 hours)  
Office Tel 011 (31-43) 356-6845  
Cell Tel 011 (31) 6 5155-9936  
Office Fax 011 (31-43) 356-6521  
eric.waldkoetter@medtronic.com